A Woman With Late-Stage Alzheimer’s Hadn’t Spoken in Years. Then She Had a Psilocybin Mushroom Trip.

An elderly woman with a decade of Alzheimer’s disease behind her, including five years spent barely speaking a full sentence, suddenly woke up in the early hours of the morning and talked for nearly four hours straight. She recognized family members. She dressed herself. After more than five years of wearing diapers around the clock, she was continent again. And it all started about 19 hours after she swallowed a dose of psilocybin-containing mushrooms.

The case is extraordinary because of how far gone she was thought to be. Advanced Alzheimer’s disease, the kind that reduces a person to near-total dependence and a blank emotional expression, is generally considered a one-way street. Doctors don’t expect meaningful recovery. Families learn to grieve someone who is still alive. Published in the journal Frontiers in Neuroscience, this case doesn’t overturn that reality, and the researchers who documented it are careful to say so.

But what happened to this woman is difficult to ignore.

She was a woman in her eighties of Japanese-American heritage, living under continuous family and caregiver supervision. Her cognitive decline had been progressing for roughly ten years, and for the last five of those years, her condition had become severe. She had trouble swallowing, couldn’t walk without help, showed almost no emotional expression, and communicated almost exclusively in single syllables. Then, in what the authors describe as an exploratory and observational intervention, she was given a dose of psilocybin-containing mushrooms, the kind that contain the same active compound studied in clinical trials for depression and anxiety.

After the First Psilocybin Mushroom Dose

Her first session involved a single oral dose of 5 grams of psilocybin-containing mushrooms, a relatively high amount compared with doses typically used in modern clinical research. Enigma was the strain used. In the hours after she took it, her body went through an intense physical response: suspected high fever, heavy sweating, and what appeared to be a deep, prolonged sleep-like state. Caregivers had no exact temperature measurements, but the physical signs were hard to miss.

Then, at approximately 3:30 in the morning, around 19 hours after she had taken the mushrooms, she woke up on her own and started talking. Not one-word responses. Full autobiographical conversation that lasted roughly four hours! She was recounting her own life.

What followed in the coming days read like a slow-motion awakening. On day one, her alertness improved and she was recognizing family members. By day two, she was walking on her own. By days two and three, she was dressing herself and showing spontaneous initiative, things she had not done in years. Also around that time, for the first time in more than five years, her diapers stayed dry, including overnight.

By days six and seven, she was asking questions like “Where did Celso go?”, correctly recalling a real person, and she was correctly identifying a vehicle. She was making sustained eye contact and smiling back at people. Across the behaviors caregivers and clinicians observed, she seemed more present than she had been in years.

A Second Session, and She Was Cracking Jokes

One month after the first session, she remained noticeably improved compared to where she had started. Urinary continence, in particular, had held. A second supervised session was then conducted, this time with 3 grams of the mushrooms.

During that second session, something unexpected happened: she described emotionally vivid, positive imagery: surfing with her son on a peaceful island. She was cracking jokes. She was walking with greater ease. Her face was alive with expression in a way it hadn’t been before. She spontaneously said, “It is pleasant to come here.”

Improvements spanned multiple major categories: movement, memory, emotional responsiveness, self-care, bladder control, social awareness, and language. Return of urinary continence, even if temporary, stood out to the researchers. Regaining that kind of control requires the brain to coordinate several systems at once, systems that are typically among the first to break down in Alzheimer’s.

Psilocybin and the Alzheimer’s Brain

Researchers are explicit that this is not evidence of a cure, or even of slowing the disease. Physical damage accumulating in the brain over years was not reversed. What they suggest instead is something worth sitting with: even in the most advanced stages of Alzheimer’s, some functional capacity may still be locked inside the brain, temporarily unreachable but not entirely gone. Under the right conditions, they propose, that capacity might briefly become accessible again.

Psilocybin can temporarily alter how large-scale brain networks communicate. It loosens the rigid patterns that normally govern brain activity, creating a kind of temporary reorganization. Researchers studying it in healthy volunteers have found that it increases what they call global brain integration, meaning more parts of the brain talking to each other at once. Authors of this case report suggest that same process might explain what happened with this patient.

No serious lasting side effects were reported. No prolonged agitation, no cardiovascular problems, no psychotic symptoms that persisted after the session. Authors note that this intervention took place outside of a formal clinical trial, without standard safety monitoring equipment.

This is a single case: one woman, one set of observations, no comparison group, no brain scans, no formal cognitive testing with standardized scales. Science builds on patterns, and a single case cannot establish one. It is entirely possible that the improvements were a coincidence, a natural fluctuation in her condition that happened to occur at the same time. Alzheimer’s disease, even in advanced stages, can involve some degree of variability.

Authors are fully transparent about all of this. They describe their report as “a detailed observational description intended to generate hypotheses for future controlled investigation.” In plain terms: this is a starting point, not a finish line. What it does is make a compelling argument that the question deserves to be studied properly.

For the millions of families watching a loved one disappear into the late stages of Alzheimer’s disease, the idea that something might still be reachable inside that silence is both achingly hopeful and a reminder of how badly controlled research in this space is needed.

Disclaimer: This article is for general information only and is not medical advice or a recommendation to use psilocybin, which remains a controlled substance. Events described here come from a single, unverified case report carried out outside a clinical trial. Always talk to your doctor first before making any changes to your health routines.

---